Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)
Status:
Completed
Trial end date:
2017-06-07
Target enrollment:
Participant gender:
Summary
This study is a Phase II, placebo-controlled, double-blind, randomized trial in 480
participants with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents
(for example, diabetes and familial hypercholesterolemia) and elevated LDL-C despite maximum
tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability
of ALN-PCSSC injection(s).